Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Cost of Revenue (2016 - 2025)

Fortress Biotech (FBIO) has 10 years of Cost of Revenue data on record, last reported at $5.8 million in Q3 2025.

  • For Q3 2025, Cost of Revenue rose 8.89% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $20.2 million, up 4.68%, while the annual FY2024 figure was $20.9 million, 8.8% down from the prior year.
  • Cost of Revenue reached $5.8 million in Q3 2025 per FBIO's latest filing, up from $4.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $11.2 million in Q3 2021 and bottomed at $2.2 million in Q4 2023.
  • Average Cost of Revenue over 5 years is $6.5 million, with a median of $6.4 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: skyrocketed 399.87% in 2021, then crashed 70.87% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $9.5 million in 2021, then dropped by 18.97% to $7.7 million in 2022, then plummeted by 70.87% to $2.2 million in 2023, then skyrocketed by 108.19% to $4.7 million in 2024, then increased by 22.97% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $5.8 million in Q3 2025, $4.9 million in Q2 2025, and $4.8 million in Q1 2025.